Safety and utility of the alpha-replacer for treatment of intraluminal obstruction of peritoneal catheters by fibrin clots

• Published in: Clinical and experimental nephrology 2021-04, Vol.25 (4), p.418-427
• Main Authors: Asai, Akimasa, Kinashi, Hiroshi, Suzuki, Yasuhiro, Kojima, Hiroshi, Sato, Yuka, Matsuoka, Naoya, Asai, Nao, Kuroyanagi, Yuki, Yamaguchi, Makoto, Nobata, Hironobu, Katsuno, Takayuki, Ishimoto, Takuji, Mizuno, Masashi, Ito, Yasuhiko
• Format: Article
• Language: English
• Subjects: Catheters; Fibrin; Medicine; Medicine & Public Health; Nephrology; Occlusion; Original Article; Peritoneal dialysis; Peritoneum; Renal function; t-Plasminogen activator; Urology
• ISSN: 1342-1751; 1437-7799
• DOI: 10.1007/s10157-020-02001-8

Background The Moncrief-Popovich technique of peritoneal catheter implantation has beneficial effects for peritoneal dialysis (PD) initiation. However, it might increase the risk of peritoneal catheter obstruction by fibrin clots, because the catheter is buried under the skin for several weeks to months. Effects of treatment of intraluminal occlusion of PD catheters with tissue plasminogen activator, recommended by the International Society for Peritoneal Dialysis guidelines/recommendations are reportedly limited. We investigated the effectiveness of the ‘alpha-replacer’ (JMS, Tokyo, Japan) for PD catheter obstruction. Methods We retrospectively analyzed a total of 193 patients in whom PD was initiated. PD catheters were embedded using the Moncrief-Popovich technique in 130 of these patients. We assessed the occurrence rates of peritoneal catheter obstruction and the utility of the alpha-replacer for treating intraluminal catheter occlusion by fibrin clots. Results Catheter obstruction occurred in eight cases with embedded catheters, one due to omental wrapping and the others due to fibrin clots, in which median catheter burial durations were 477 (interquartile range [IQR], 226–510) days. All catheter obstructions due to fibrin clots were successfully treated with the alpha-replacer, leading to improved catheter drainage. The median amount of contrast agent used in catheterography was 10 (IQR 9–10) mL, which did not adversely affect residual renal function. There were no complications. No recurrence occurred during the observation period (median 111, IQR 55.5–141 months). Conclusion Our results suggest that treatment with the alpha-replacer is a safe and effective treatment option for intraluminal obstruction of PD catheters by fibrin clots.